Genscript Biotech Corporation Cash Flow-to-Debt Ratio
Genscript Biotech Corporation cash flow-to-debt ratio. Genscript Biotech Corporation (G51) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2023, meaning its operating cash flow of €-93.58 Million could theoretically repay 0% of its total liabilities (€1.30 Billion) in one year. Check how high is Genscript Biotech Corporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Genscript Biotech Corporation (2016–2025)
Cash flow-to-debt ratio of Genscript Biotech Corporation from 2016 to 2025. Historical debt coverage capacity for Genscript Biotech Corporation across 10 annual periods. Check cash flow reinvestment rate of Genscript Biotech Corporation to assess the company's total reinvestment commitment from operating cash flow.
Genscript Biotech Corporation Cash Flow-to-Debt Ratio by Year (2016–2025)
Genscript Biotech Corporation cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Genscript Biotech Corporation. For the full cash flow conversion analysis, see cash efficiency ratio of Genscript Biotech Corporation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | €325.52 Million | €888.59 Million | ▲ +362.4% |
| 2024 | 0.08x | €75.65 Million | €954.91 Million | ▲ +137.1% |
| 2023 | -0.21x | €-286.91 Million | €1.34 Billion | ▼ -110.2% |
| 2022 | -0.10x | €-120.29 Million | €1.18 Billion | ▲ +15.3% |
| 2021 | -0.12x | €-136.79 Million | €1.14 Billion | ▲ +49.8% |
| 2020 | -0.24x | €-151.09 Million | €631.82 Million | ▼ -312.8% |
| 2019 | -0.06x | €-29.95 Million | €517.11 Million | ▼ -108.0% |
| 2018 | 0.73x | €307.66 Million | €423.68 Million | ▲ +837.8% |
| 2017 | 0.08x | €21.37 Million | €275.94 Million | ▼ -90.2% |
| 2016 | 0.79x | €33.27 Million | €42.01 Million | — |